Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
24
pubmed:dateCreated
2009-6-12
pubmed:abstractText
Ligation of inhibitory receptors renders natural killer (NK) cells inactive against autologous tumors. Recently, the proteasome inhibitor bortezomib was shown to sensitize tumors to autologous NK-cell cytotoxicity in vitro. Here, we show bortezomib augments the antitumor effects of syngeneic NK-cell infusions in tumor-bearing animals; this effect is further enhanced in regulatory T cell (Treg cell)-depleted hosts. In vitro, bortezomib-treated tumors had higher tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and perforin/granzyme-mediated caspase-8 activity, which enhanced their susceptibility to NK-cell lysis. Bioluminescence imaging of mice with established tumors showed treatment with bortezomib and syngeneic NK cells reduced tumor growth and prolonged survival compared with controls receiving bortezomib or NK cells alone. In contrast, tumor progression was not delayed when animals received bortezomib and perforin-deficient NK cells, showing drug-induced augmentation in NK-cell cytotoxicity was mediated through perforin/granzyme. Furthermore, tumor growth was slower in bortezomib-treated recipients when host Treg cells were eradicated with anti-CD25 antibody before infusing NK cells compared with mice without Treg-cell ablation (tumor doubling time, 16.7 vs 4.9 days, respectively; P = .02). These findings suggest that depletion of Treg cells followed by bortezomib-induced tumor sensitization to autologous NK cells could be used as a novel strategy to treat cancer.
pubmed:commentsCorrections
http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-10381530, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-10548502, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-11114298, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-11221844, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-11513144, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-11562487, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-11896281, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-12637321, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-12689936, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-12714493, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-15016654, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-15308119, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-15632206, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-15731175, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-15977644, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-16424187, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-16510567, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-16567639, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-16698441, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-16699949, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-1684377, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-16849582, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-16888019, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-17179231, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-17237443, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-17371948, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-17412888, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-17510429, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-18097016, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-18445820, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-19520810, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-3549961, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-6965957, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-9464839, http://linkedlifedata.com/resource/pubmed/commentcorrection/19202127-9539768
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
AIM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Jun
pubmed:issn
1528-0020
pubmed:author
pubmed:issnType
Electronic
pubmed:day
11
pubmed:volume
113
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
6120-7
pubmed:dateRevised
2010-9-23
pubmed:meshHeading
pubmed-meshheading:19202127-Adoptive Transfer, pubmed-meshheading:19202127-Animals, pubmed-meshheading:19202127-Antineoplastic Agents, pubmed-meshheading:19202127-Apoptosis, pubmed-meshheading:19202127-Blotting, Western, pubmed-meshheading:19202127-Boronic Acids, pubmed-meshheading:19202127-Carcinoma, Lewis Lung, pubmed-meshheading:19202127-Caspase 8, pubmed-meshheading:19202127-Cell Proliferation, pubmed-meshheading:19202127-Granzymes, pubmed-meshheading:19202127-Humans, pubmed-meshheading:19202127-Kidney Neoplasms, pubmed-meshheading:19202127-Killer Cells, Natural, pubmed-meshheading:19202127-Lymphocyte Depletion, pubmed-meshheading:19202127-Lymphocytes, Tumor-Infiltrating, pubmed-meshheading:19202127-Mice, pubmed-meshheading:19202127-Mice, Inbred BALB C, pubmed-meshheading:19202127-Mice, Inbred C57BL, pubmed-meshheading:19202127-Pyrazines, pubmed-meshheading:19202127-T-Lymphocytes, Regulatory
pubmed:year
2009
pubmed:articleTitle
Bortezomib treatment and regulatory T-cell depletion enhance the antitumor effects of adoptively infused NK cells.
pubmed:affiliation
Hematology Branch, National Heart, Lung, and Blood Institute, National Institutes of Health, Bethesda, MD 20892-1202, USA.
pubmed:publicationType
Journal Article, Research Support, Non-U.S. Gov't, Research Support, N.I.H., Intramural